Several African countries, including Kenya, have been selected for the rollout of Lenacapavir, a long-acting injectable HIV pre-exposure prophylaxis (PrEP).
The countries identified are Nigeria, Uganda, Kenya, Mozambique, Zimbabwe, South Africa, Eswatini and Lesotho.
Lenacapavir is designed for HIV-negative individuals at risk of infection and is administered as a preventive measure.
Health experts emphasise that it is neither a vaccine nor a cure for HIV, but a preventive option aimed at reducing new infections.
The injectable PrEP offers long-acting protection, marking a significant step in expanding HIV prevention choices, particularly in high-burden regions.
The drug was approved by the United States Food and Drug Administration (FDA) in June 2025.
It was later endorsed in the updated World Health Organization (WHO) guidelines released in July 2025.
The selection of the African nations signals efforts to widen access to innovative HIV prevention tools and strengthen the fight against new infections across the continent.
Comments 0
Sign in to join the conversation
Sign In Create AccountNo comments yet. Be the first to share your thoughts!